



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

# Travel Medicine and Infectious Disease

journal homepage: [www.elsevier.com/locate/tmaid](http://www.elsevier.com/locate/tmaid)

## Sweet syndrome in post-COVID-19 infection: A case report

### ARTICLE INFO

#### Keywords

Sweet syndrome

COVID-19

Neutrophilic dermatosis

#### Dear editor:

The novel coronavirus (SARS-CoV-2), the cause of coronavirus 2019 disease (COVID-19) pandemic, is associated with some cutaneous manifestations. The most frequently reported are: acral lesions, maculopapular rashes, urticarial rashes, vascular lesions and vesicular rashes [1]. The occurrence of sweet syndrome in the context of a covid infection of which we report a case is rare; only two cases have been reported in the literature [2,3]. We report here a case of Sweet's syndrome occurring three weeks after a simple coronavirus disease 2019 (COVID-19) infection.

A 61-year-old patient with no particular history who presented three weeks after a simple COVID-19 infection confirmed by positive RT-PCR in nasopharyngeal swabs, made up of fever, cough myalgia and without severe respiratory syndrome, painful erythematous, edematous, purplish plaques in the hands and feet (Fig. 1). The biological assessment found an inflammatory syndrome with a CRP of 105 mg, hyperleukocytosis predominantly neutrophilic. The ASLO assay was negative. A thoraco-abdomino-pelvic scanner, performed to rule out associated malignancies, showed no abnormalities. Protein electrophoresis was normal. The patient did not have any history of inflammatory bowel disease or digestive sign, and faecalcal protectin was negative. No supplementary drugs were added to what was indicated above. Pathological examination of a skin biopsy found an inflammatory dermal neutrophilic infiltrate without vasculitis. A Sweet post covid syndrome was retained in view of the clinical and anatomopathological elements. Colchicine treatment was started with marked improvement.

Sweet's syndrome also known as acute febrile neutrophilic dermatosis is a rare neutrophilic dermatosis characterized by a constellation of clinical symptoms, physical features, and pathologic findings which include fever, neutrophilia, tender erythematous skin lesions (papules, nodules, and plaques) most often on face and upper extremities. Histologically, we note a diffuse infiltrate consisting predominantly of mature neutrophils that are typically located in the upper dermis without vasculitis. The cause of this syndrome remains unknown in most cases. However, it has been associated with inflammatory diseases, haematological or visceral malignancies, pregnancy, drug exposure, upper respiratory and gastrointestinal infections [4]. Taşkın et al. [2] reported the first case of sweet's syndrome concomitant with SARS-CoV-2 infection in a 61-yearold woman. Simar Berro et al. [3] have published sweet's

syndrome three weeks after a severe COVID-19 infection. The mechanism of Sweet's syndrome remains unknown; it seems to be related to a hypersensitivity reaction triggered by infections, neoplastic processes or by drug intake leading to the secretion of cytokines and activation of PNN. Granulocyte colony stimulating factors (G-CSF) is a specific factor in the growth of neutrophils that plays a crucial role in the pathogenesis of Sweet syndrome, however several cases of Sweet syndrome have been reported following administration of GM-CSF [5] and several studies have shown an increase in GM-CSF levels in the acute phase of Sweet syndrome. GM-CSF stimulates the production, activation and chemotaxis of neutrophils that accumulate in the dermis [6,7]. The pathogenesis of sweet syndrome in Covid 19 infection is unclear but is likely the result of cytokine storm and immunologic abnormalities. The aberrant host in response in COVID-19 infection was proposed to be centred around neutrophils. In autopsy specimens, neutrophil infiltration in pulmonary capillaries, extravasation of neutrophils to alveolar space and capillaritis with fibrin deposition were shown [8,9].

We describe here a typical Sweet's syndrome occurring three weeks after COVID-19 infection and we very likely think of a causal link between the two events given that associated malignancy and inflammatory bowel disease were ruled out and the possible involvement of the administered drugs was investigated, but no strong evidence was found in terms of extrinsic and intrinsic imputability.

#### Statement of ethics

The patient's consent was obtained for the pictures and eventual publication.

#### Disclosure statement

The authors have no conflicts of interest to declare.

#### Funding sources

The authors did not receive any funding.

<https://doi.org/10.1016/j.tmaid.2021.102188>

Received 16 October 2021; Received in revised form 18 October 2021; Accepted 19 October 2021

Available online 22 October 2021

1477-8939/© 2021 Elsevier Ltd. All rights reserved.



Fig. 1. Edematous purplish plaques of hands.

#### Author contributions

All authors also state that they have read and approved the final version of the manuscript.

#### Acknowledgement

We are indebted to the patient for giving us the consent for publication.

#### References

- [1] Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol* 2020;34:212–3.
- [2] Taşkın B, Vural S, Altuğ E, Demirkesen C, Kocatürk E, Çelebiî, et al. COVID 19 Presenting with Atypical Sweet's Syndrome. *J Eur Acad Dermatol Venereol* 2020;10: 534–5.
- [3] Berro S, Calas A, Sohier P, Darbord D, Dupin N. Sweet's syndrome three weeks after a severe COVID-19 infection: a case report. *Acta Derm Venereol* 2021;101(6):1–2.
- [4] Lang Caroline, Quenan Sandrine. Sweet's syndrome, a diagnosis to keep in mind. *Rev Med Suisse* 2017 Mar 29;13(556):678–83.
- [5] Arbetter KR, Hubbard KW, Markovic SN, Gibson LE, Phyllyk RL. Case of granulocyte colony-stimulating factor-induced Sweet's syndrome. *Am J Hematol* 1999;61(2): 126–9.
- [6] Reuss-Borst MA, Muller CA, Waller HD. The possible role of G-CSF in the pathogenesis of Sweet's syndrome. *Leuk Lymphoma* 1994;15(3–4):261–4.
- [7] Reuss-Borst MA, Pawelec G, Saal JG, Horny HP, Muller CA, Waller HD. Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. *Br J Haematol* 1993;84(2):356–8.
- [8] Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. *J Exp Med* 2020:217.
- [9] Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Vander Heide RS. Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. 2020.

Fatima-Zahra Agharbi<sup>\*</sup>, Kenza Oqbani, Abir Allaoui, Inas Chikhaoui, Soumiya Chiheb  
*Sheikh Khalifa Hospital, Faculty of Medicine, Mohamed VI University of Health Sciences, Casablanca, Morocco*

<sup>\*</sup> Corresponding author.  
 E-mail address: [aghmarifz@gmail.com](mailto:aghmarifz@gmail.com) (F.-Z. Agharbi).